Ameriprise
SGYP

Ameriprise’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Ameriprise’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-260,094
Closed -$1.21M – 3830
2017
Q1 		$1.21M Buy
260,094
+25,134
+11% +$146K ﹤0.01% 2808
2016
Q4 		$1.43M Sell
234,960
-20,935
-8% -$109K ﹤0.01% 2791
2016
Q3 		$1.41M Buy
255,895
+238,505
+1,372% +$1.12M ﹤0.01% 2749
2016
Q2 		$66K Sell
17,390
-1,540
-8% -$5.22K ﹤0.01% 3665
2016
Q1 		$52K Sell
18,930
-293,329
-94% -$1.06M ﹤0.01% 3670
2015
Q4 		$1.77M Buy
312,259
+21,591
+7% +$132K ﹤0.01% 2671
2015
Q3 		$1.54M Sell
290,668
-42,235
-13% -$327K ﹤0.01% 2770
2015
Q2 		$2.76M Buy
332,903
+276,038
+485% +$1.34M ﹤0.01% 2552
2015
Q1 		$263K Buy
56,865
+46,285
+437% +$151K ﹤0.01% 3481
2014
Q4 		$32K Buy
10,580
+10,560
+52,800% +$31.2K ﹤0.01% 3646
2014
Q3 		$0 Sell
20
-180
-90% -$653 ﹤0.01% 5955
2014
Q2 		$1K Buy
+200
New +$850 ﹤0.01% 5430
2013
Q4 		– Sell
-5,092
Closed -$23K – 5551
2013
Q3 		$23K Hold
5,092
– – ﹤0.01% 4329
2013
Q2 		$22K Buy
+5,092
New +$25.6K ﹤0.01% 4218

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ameriprise's SGYP Position: Q2 2017 in Review

Ameriprise sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2017, closing a stake of 260,094 shares — an estimated $1.21M sold.

Ameriprise first reported a position in SGYP in Q2 2013 and held it in 14 quarters. The position peaked at $2.76M in Q2 2015. 146 funds tracked by Wall St. Rank hold SGYP as of Q2 2017.

  • Ameriprise reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2017 after selling out during the quarter.
  • Ameriprise sold 260,094 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2017, an estimated $1.21M.
  • Ameriprise first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 14 quarters.
  • Ameriprise's Synergy Pharmaceuticals, Inc Common Stock position peaked at $2.76M in Q2 2015.
  • 146 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2017.

Based on Ameriprise's 13F filing for Q2 2017, filed 10 Aug 2017.